TSHA
Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, Taysha aims to rapidly translate our treatments from bench to bedside. Taysha Gene Therapies has combined its team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, Taysha Gene Therapies leverages its fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives.
Taysha Gene Therapies, Inc. (TSHA) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (D). The rating has held at C- for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | D (1.4) | C- (2.1) | C (2.4) | D+ (1.6) | C+ (2.6) | C- (2.1) |
| 2026-11-08 | D (1.5) | D+ (1.8) | C (2.5) | C- (1.9) | C+ (2.6) | C- (2.0) |
| 2026-11-01 | D (1.4) | D+ (1.7) | C+ (2.5) | C- (2.0) | C+ (2.7) | C- (2.1) |
| 2026-10-25 | D+ (1.5) | D+ (1.7) | C+ (2.5) | D+ (1.8) | C+ (2.6) | C- (2.1) |
| 2026-10-18 | D+ (1.8) | D+ (1.7) | C+ (2.5) | D+ (1.8) | C+ (2.6) | C- (2.1) |